Regulatory resistance reshaped a month of contested takeovers

Jun 30 - Jul 31across 5 weeksImpact

Paramount-Warner Hits a Court-Ordered Halt

Paramount-Warner moved from regulatory remedies and a cleared closing delay into consolidated antitrust litigation. A judge then blocked the acquisition, prompting Paramount to pause the deal and accept a possible closing date as late as June 2027.

43 storiesJun 29 Jul 6 Jul 13 Jul 20 Jul 27

Jun 29 - Jul 23across 3 weeksImpact

EasyJet Becomes a Two-Bidder Contest

EasyJet shifted from an agreement in principle with Castlelake to backing Apollo's higher £5.7 billion offer. The resulting bidding race then encountered possible EU ownership scrutiny, adding execution risk to the price contest.

11 storiesJun 29 Jul 6 Jul 13 Jul 20

Jul 6 - Jul 22across 2 weeksImpact

Prologis Escalates Its Segro Takeover

Segro rejected repeated approaches while disputing Prologis's valuation assumptions. Prologis then raised its offer to about £14 billion and called it best and final, putting direct pressure on Segro's board and shareholders.

6 storiesJul 6 Jul 13 Jul 20

Jul 27 - Jul 28Impact

Private-Market Platforms Consider Mega-Mergers

Private-market consolidation talks expanded from Ares discussions to buy Leonard Green into a broader private-credit bid for a legacy private equity firm. A completed combination could concentrate fundraising, sourcing, and financing power across the buyout industry.

2 storiesJul 27

Jun 29 - Jul 28across 3 weeksImpact

DCC Bid Heads for Shareholder Showdown

Investor opposition challenged the KKR and Energy Capital Partners bid for DCC, including after the offer was sweetened. The board eventually endorsed the £5.75 billion proposal, but shareholders still face a vote that could demand better terms or prolong the process.

4 storiesJun 29 Jul 6 Jul 13 Jul 20 Jul 27

Jul 6 - Jul 30across 2 weeksImpact

Banijay Completes All3Media Integration

Banijay's combination with All3Media progressed from an $8 billion production-group expansion plan to completed integration. The enlarged company now has greater scale across formats and buyer relationships, despite an early revenue decline.

5 storiesJul 6 Jul 13 Jul 20 Jul 27

Jul 6 - Jul 27across 3 weeksImpact

Biotech Buyers Chase Replacement Growth

Vertex's $10 billion purchase of Crinetics illustrated the premium for late-stage biotech assets. More broadly, patent expirations pushed drugmakers toward assets and platforms that could replace blockbuster medicines, with additional acquisitions following in the sector.